BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...
CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback